Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
The market for anti-obesity drugs seems to be at risk of calcifying into a dominant duopoly. Eli Lilly (LLY +0.50%) and Novo Nordisk (NVO +6.23%) split it through their...
